<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="358">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01688219</url>
  </required_header>
  <id_info>
    <org_study_id>45896566645469</org_study_id>
    <nct_id>NCT01688219</nct_id>
  </id_info>
  <brief_title>Immune Response in the SAPHO Syndrome</brief_title>
  <official_title>Immune Mechanisms During SAPHO Syndrome and Treatment by Etarnecept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aetiology of SAPHO syndrome seems to involve genetic, infectious and immunological
      components. The investigators examined innate and adaptative immune responses in SAPHO
      syndrome as compared with psoriatic arthritis and rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>IL-8 production by PMN</measure>
    <time_frame>24 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>TNFalpha production by PMN</measure>
    <time_frame>24 h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>SAPHO Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        SAPHO syndrome patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of SAPHO syndrome

          -  Must have bone lesions

        Exclusion Criteria:

          -  Infliximab treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Hayem, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assitance Publique-Hopitaux Paris</affiliation>
  </overall_official>
  <verification_date>October 2007</verification_date>
  <lastchanged_date>September 18, 2012</lastchanged_date>
  <firstreceived_date>September 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAPHO syndrome</keyword>
  <keyword>Innate immunity</keyword>
  <keyword>TNF alpha</keyword>
  <keyword>Polymorphonuclear neutrophils</keyword>
  <keyword>Propionibacterium acnes</keyword>
  <keyword>Interleukin-8</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Hyperostosis Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
